Atherosclerosis
Volume 185, Issue 2 , Pages 219-226 , April 2006

Impact of oxidized low density lipoprotein on vascular cells

Received 24 June 2005 ,Revised 29 September 2005 ,Accepted 3 October 2005.

References 

  1. Ross R. Mechanisms of disease—atherosclerosis: an inflammatory disease. N Engl J Med. 1999;340:115–126
  2. Schachinger V, Zeiher AM. Atherogenesis-recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant. 2002;17:2055–2064
  3. Caplan BA, Schwartz CJ. Increased endothelial cell turnover in areas of in vivo Evans blue uptake in the pig aorta. Atherosclerosis. 1973;17:401–417
  4. Sprague EA, Steinbach BL, Nerem RM, Schwartz CJ. Influence of a laminar steady-state fluid-imposed wall shear stress on the binding, internalization, and degradation of low density lipoproteins by cultured arterial endothelium. Circulation. 1987;76:648–656
  5. Kockx MM, De Meyer GRY, Muhring J, et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998;97:2307–2315
  6. Crisby M, Kallin B, Thyberg J, et al. Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis. 1997;130:17–27
  7. Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med. 2002;8:1249–1256
  8. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med. 1996;20:707–727
  9. Shackelford RE, Kaufmann WK, Paules RS. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med. 2000;28:1387–1404
  10. Ylä-Herttuala S, Palinski W, Rosenfeld ME, et al. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest. 1989;84:1086–1095
  11. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(A) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579–592
  12. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms: oxidation, inflammation, and genetics. Circulation. 1995;91:2488–2496
  13. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915–924
  14. Galle J, Wanner C. Oxidized LDL and Lp(a)—preparation, modification, and analysis. In:  Armstrong D editors. Free radical and antioxidant protocols. Totowa, NJ: Humana Press; 1998;p. 119–130
  15. Klouche M, May AE, Hemmes M, et al. Enzymatically modified, nonoxidized LDL induces selective adhesion and transmigration of monocytes and T-lymphocytes through human endothelial cell monolayers. Arterioscler Thromb Vasc Biol. 1999;19:784–793
  16. Berliner JA, Territo MC, Sevanian A, et al. Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest. 1990;85:1260–1266
  17. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29–38
  18. Carr AC, McCall MR, Frei B. Oxidation of LDL by myeloperoxidase and reactive nitrogen species—reaction pathways and antioxidant protection. Arterioscler Thromb Vasc Biol. 2000;20:1716–1723
  19. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase—role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
  20. Vásquez-Vivar J, Kalyanaraman B. Generation of superoxide from nitric oxide synthase. FEBS Lett. 2000;481:305–306
  21. Böger RH, Böde-Boger SM, Phivthong-ngam L, et al. Dietary l-arginine and α-tocopherol reduce vascular oxidative stress and preserve endothelial function in hypercholesterolemic rabbits via different mechanisms. Atherosclerosis. 1998;141:31–43
  22. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers—evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36–E41
  23. Fleming I, Mohamed A, Galle J, et al. Oxidized low-density lipoprotein increases superoxide production by endothelial nitric oxide synthase by inhibiting PKC alpha. Cardiovasc Res. 2005;65:897–906
  24. Lander HM. An essential role for free radicals and derived species in signal transduction. FASEB J. 1997;11:118–124
  25. Griendling KK, FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation. 2003;108:1912–1916
  26. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109:3164–3170
  27. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546–2551
  28. Mügge A, Brandes RP, Böger RH, et al. Vascular release of superoxide radicals is enhanced in hypercholesterolemic rabbits. J Cardivasc Pharmacol. 1994;24:994–998
  29. Hansen PR, Kharazmi AK, Jauhiainen M, Ehnholm C. Induction of free radical generation in human monocytes by lipoprotein(a). Eur J Clin Invest. 1994;24:497–499
  30. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a)—role of oxygen-derived radicals. Circulation. 1995;92:1582–1589
  31. Maeba R, Maruyama A, Tarutani O, Ueta N, Shimasaki H. Oxidized low-density lipoprotein induces the production of superoxide by neutrophils. FEBS Lett. 1995;377:309–312
  32. Galle J, Heinloth A, Schwedler S, Wanner C. Effect of HDL and atherogenic lipoproteins on formation of O2− and renin release in juxtaglomerular cells. Kidney Int. 1997;51:253–260
  33. Kinscherf R, Deigner HP, Usinger C, et al. Induction of mitochondrial manganese superoxide dismutase in macrophages by oxidized LDL: its relevance in atherosclerosis of humans and heritable hyperlipidemic rabbits. FASEB J. 1997;11:1317–1328
  34. Cominacini L, Garbin U, Pasini AF, et al. Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: inhibitory effect of lacidipine. J. Hypertens. 1998;16:1913–1919
  35. Galle J, Schneider R, Heinloth A, et al. Lp(a) and LDL induce apoptosis in human endothelial cells and in rabbit aorta: role of oxidative stress. Kidney Int. 1999;55:1450–1461
  36. Cominacini L, Pasini AF, Garbin U, et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem. 2000;275:12633–12638
  37. Sharma P, Reddy K, Franki N, et al. Native and oxidized low density lipoproteins modulate mesangial cell apoptosis. Kidney Int. 1996;50:1604–1611
  38. Parthasarathy S, Steinbrecher U, Barnett J, Witztum JL, Steinberg D. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA. 1985;82:3000–3004
  39. Yokoyama M, Hirata K, Miyake R, et al. Lysophosphatidylcholine: essential role in the inhibition of endothelium-dependent vasorelaxation by oxidized low density lipoprotein. Biochem Biophys Res Commun. 1990;168:301–308
  40. Esterbauer H, Jürgens G, Quehenberger O, Koller E. Autoxidation of human low density lipoprotein: loss of polyunsaturated fatty acids and Vitamin E and generation of aldehydes. J Lipid Res. 1987;28:495–509
  41. Kugiyama K, Sugiyama S, Ogata N, et al. Burst production of superoxide anion in human endothelial cells by lysophosphatidylcholine. Atherosclerosis. 1999;143:201–204
  42. Ohara Y, Peterson TE, Zheng B, Kuo JF, Harrison DG. Lysophosphatidylcholine increases vascular superoxide anion production via protein kinase C activation. Arterioscler Thromb. 1994;14:1007–1013
  43. Heinloth A, Heermeier K, Raff U, Wanner C, Galle J. Stimulation of NADPH oxidase by oxidized low-density lipoprotein induces proliferation of human vascular endothelial cells. J Am Soc Nephrol. 2000;11:1819–1825
  44. Rueckschloss U, Galle J, Holtz J, Zerkowski HR, Morawietz H. Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells—antioxidative potential of hydroxymethylglutaryl coenzyme a reductase inhibitor therapy. Circulation. 2001;104:1767–1772
  45. Stuehr D, Pou S, Rosen GM. Oxygen reduction by nitric-oxide synthases. J Biol Chem. 2001;276:14533–14536
  46. Ohba M, Shibanuma M, Kuroki T, Nose K. Production of hydrogen peroxide by transforming growth factor-beta 1 and its involvement in induction of egr-1 in mouse osteoblastic cells. J Cell Biol. 1994;126:1079–1088
  47. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 1994;74:1141–1148
  48. Sundaresan M, Yu ZX, Ferrans VJ, Irani K, Finkel T. Requirement for generation of H2O2 for platelet-derived growth factor signal transduction. Science. 1995;270:296–299
  49. Lo YY, Cruz TF. Involvement of reactive oxygen species in cytokine and growth factor induction of c-fos expression in chondrocytes. J Biol Chem. 1995;270:11727–11730
  50. Thannickal VJ, Fanburg BL. Activation of an H2O2-generating NADH oxidase in human lung fibroblasts by transforming growth factor beta 1. J Biol Chem. 1995;270:30334–30338
  51. Cominacini L, Rigoni A, Pasini AF, et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox- LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem. 2001;276:13750–13755
  52. Thum T, Borlak J. Mechanistic role of cytochrome P450 monooxygenases in oxidized low-density lipoprotein-induced vascular injury: therapy through LOX-1 receptor antagonism?. Circ Res. 2004;94:e1–e13
  53. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141–1146
  54. Zoccali C, Bode-Boger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358:2113–2117
  55. Boger RH, Sydow K, Borlak J, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87:99–105
  56. Scalera F, Borlak J, Beckmann B, et al. Endogenous nitric oxide synthesis inhibitor asymmetric dimethyl l-arginine accelerates endothelial cell senescence. Arterioscler Thromb Vasc Biol. 2004;24:1816–1822
  57. Smirnova IV, Sawamura T, Goligorsky MS. Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in endothelial cells by nitric oxide deficiency. Am J Physiol Renal Physiol. 2004;287:F25–F32
  58. el Saadani M, Esterbauer H, el Sayed M, et al. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627–630
  59. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381–1478
  60. De Grey AD. HO2: the forgotten radical. DNA Cell Biol. 2002;21:251–257
  61. Roginsky V, Barsukova T. Superoxide dismutase inhibits lipid peroxidation in micelles. Chem Phys Lipids. 2001;111:87–91
  62. Pastor I, Esquembre R, Micol V, Mallavia R, Mateo CR. A ready-to-use fluorimetric biosensor for superoxide radical using superoxide dismutase and peroxidase immobilized in sol–gel glasses. Anal Biochem. 2004;334:335–343
  63. Jezek P, Hlavata L. Mitochondria in homeostasis of reactive oxygen species in cell, tissues, and organism. Int J Biochem Cell Biol. 2005;
  64. Ichikawa I, Kiyama S, Yoshioka T. Renal antioxidant enzymes: their regulation and function. Kidney Int. 1994;45:1–9
  65. Witko Sarsat V, Friedlander M, Capeillere Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49:1304–1313
  66. Moriyama T, Kawada N, Nagatoya K, et al. Oxidative stress in tubulointerstitial injury: therapeutic potential of antioxidants towards interstitial fibrosis. Nephrol Dial Transplant. 2000;15(Suppl. 6):47–49
  67. Toborek M, Wasik T, Drózdz M, et al. Effect of hemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism. 1992;41:1229–1232
  68. Epperlein MM, Nourooz-Zadeh J, Jayasena SD, et al. Nature and biological significance of free radicals generated during bicarbonate hemodialysis. J Am Soc Nephrol. 1998;9:457–463
  69. Hannken T, Schroeder R, Stahl RAK, Wolf G. Angiotensin II-mediated expression of p27Kip1 induction of cellular hypertrophy in renal tubular cells depend on the generation of oxygen radicals. Kidney Int. 1998;54:1923–1933
  70. Chua CC, Hamdy RC, Chua BH. Upregulation of vascular endothelial growth factor by H2O2 in rat heart endothelial cells. Free Radic Biol Med. 1998;25:891–897
  71. Ushio-Fukai M, Tang Y, Fukai T, et al. Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ Res. 2002;91:1160–1167
  72. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab. 1997;23:140–143
  73. Klahr S, Morrissey JJ. The role of vasoactive compounds, growth factors and cytokines in the progression of renal disease. Kidney Int Suppl. 2000;75:S7–S14
  74. Boonstra J, Post JA. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene. 2004;337:1–13
  75. Aronis A, Madar Z, Tirosh O. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med. 2005;38:1221–1230
  76. Brandes RP, Viedt C, Nguyen K, et al. Thrombin-induced MCP-1 expression involves activation of the p22phox-containing NADPH oxidase in human vascular smooth muscle cells. Thromb Haemost. 2001;85:1104–1110
  77. Heinloth A, Fischer B, Brüne B, Galle J. Nitric oxide prevents oxidized LDL-induced p53 accumulation, cytochrome c translocation, and apoptosis in macrophages via guanylate cyclase stimulation. Atherosclerosis. 2002;162:93–101
  78. Galle J, Heinloth A, Wanner C, Heermeier K. Dual effect of oxidized LDL on cell cycle in human endothelial cells through oxidative stress. Kidney Int. 2001;59:S120–S123
  79. Wolf G, Shankland SJ. p27Kip1: the “rosebud” of diabetic nephropathy?. J Am Soc Nephrol. 2003;14:819–822
  80. Shankland SJ, Wolf G. Cell cycle regulatory proteins in renal disease: role in hypertrophy, proliferation, and apoptosis. Am J Physiol Renal Physiol. 2000;278:F515–F529
  81. Rosenblatt J, Gu Y, Morgan DO. Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA. 1992;89:2824–2828
  82. Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA, Dang CV. Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci USA. 1994;91:6875–6879
  83. Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R. Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA. 1994;91:3754–3758
  84. Shi L, Chen G, He D, et al. Granzyme B induces apoptosis and cyclin A-associated cyclin-dependent kinase activity in all stages of the cell cycle. J Immunol. 1996;157:2381–2385
  85. Zhou BB, Li H, Yuan J, Kirschner MW. Caspase-dependent activation of cyclin-dependent kinases during Fas-induced apoptosis in Jurkat cells. Proc Natl Acad Sci USA. 1998;95:6785–6790
  86. Polyak K, Lee MH, Erdjument BH, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59–66
  87. Nourse J, Firpo E, Flanagan WM, et al. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570–573
  88. Johnson DG, Walker CL. Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol. 1999;39:295–312
  89. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–1512
  90. Sgambato A, Cittadini A, Faraglia B, Weinstein IB. Multiple functions of p27(Kip1) and its alterations in tumor cells: a review. J Cell Physiol. 2000;183:18–27
  91. Seibold S, Schurle D, Heinloth A, et al. Oxidized LDL induces proliferation and hypertrophy in human umbilical vein endothelial cells via regulation of p27Kip1 expression: role of RhoA. J Am Soc Nephrol. 2004;15:3026–3034
  92. Seasholtz TM, Zhang T, Morissette MR, et al. Increased expression and activity of RhoA are associated with increased DNA synthesis and reduced p27Kip1 expression in the vasculature of hypertensive rats. Circ Res. 2001;89:488–495
  93. Galle J, Mameghani A, Bolz SS, et al. Oxidized LDL and its compound lysophosphatidylcholine potentiate AngII-induced vasoconstriction by stimulation of RhoA. J Am Soc Nephrol. 2003;14:1471–1479
  94. Bishop AL, Hall A. Rho GTPases and their effector proteins. Biochem J. 2000;348(Pt 2):241–255
  95. Ishizaki T, Naito M, Fujisawa K, et al. p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett. 1997;404:118–124
  96. Nakagawa O, Fujisawa K, Ishizaki T, et al. ROCK-I and ROCK-II, two isoforms of Rho-associated coiled-coil forming protein serine/threonine kinase in mice. FEBS Lett. 1996;392:189–193
  97. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res. 2000;261:44–51
  98. Iwamoto H, Nakamuta M, Tada S, et al. A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol. 2000;32:762–770
  99. Auge N, Garcia V, Maupas-Schwalm F, et al. Oxidized LDL-induced smooth muscle cell proliferation involves the EGF receptor/PI-3 kinase/Akt and the sphingolipid signaling pathways. Arterioscler Thromb Vasc Biol. 2002;22:1990–1995
  100. Auge N, Maupas-Schwalm F, Elbaz M, et al. Role for matrix metalloproteinase-2 in oxidized low-density lipoprotein-induced activation of the sphingomyelin/ceramide pathway and smooth muscle cell proliferation. Circulation. 2004;110:571–578
  101. Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res. 2004;94:370–376
  102. Zettler ME, Prociuk MA, Austria JA, Zhong G, Pierce GN. Oxidized low-density lipoprotein retards the growth of proliferating cells by inhibiting nuclear translocation of cell cycle proteins. Arterioscler Thromb Vasc Biol. 2004;24:727–732
  103. Heistad DD, Armstrong ML, Marcus ML, Piegors DJ, Mark AL. Augmented responses to vasoconstrictor stimuli in hypercholesterolemic and atherosclerotic monkeys. Circ Res. 1984;54:711–718
  104. Rosendorff C, Hoffman JIE, Verrier ED, Rouleau J, Boerboom LE. Cholesterol potentiates the coronary artery response to norepinephrine in anesthetized and conscious dogs. Circ Res. 1981;48:320–329
  105. Shimokawa H, Tomoike H, Nabeyama S, et al. Coronary artery spasm induced in miniature swine: angiographic evidence and relation to coronary atherosclerosis. Am Heart J. 1985;110:300–310
  106. Galle J, Busse R, Bassenge E. Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different mechanisms. Arterioscler Thromb. 1991;11:1712–1718
  107. Verbeuren T, Jordaens F, Zonnekeyn L, et al. Endothelium-dependent and endothelium-independent contractions and relaxations in isolated arteries of control and hypercholesterolemic rabbits. Circ Res. 1986;58:552–564
  108. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986;250:H822–H827
  109. Flavahan NA. Atherosclerosis or lipoprotein-induced endothelial dysfunction—potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation. 1992;85:1927–1938
  110. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol. 1996;7:274–280
  111. Sachinidis A, Locher R, Mengden T, Steiner A, Vetter W. Vasoconstriction: a novel activity for low density lipoprotein. Biochem Biophys Res Commun. 1989;163:315–320
  112. Galle J, Bassenge E, Busse R. Oxidized low density lipoproteins potentiate vasoconstrictions to various agonists by direct interaction with vascular smooth muscle. Circ Res. 1990;66:1287–1293
  113. Somlyo AP, Somlyo AV. Signal transduction and regulation in smooth muscle. Nature. 1994;372:231–236[published erratum appears in Nature 1994;372(December (6508)):812]
  114. Bolz SS, Galle J, Derwand R, De Wit C, Pohl U. Oxidized LDL increase the sensitivity of the contractile apparatus in isolated resistance arteries for Ca2+ via a Rho- and Rho-kinase-dependent mechanism. Circulation. 2000;102:2402–2410
  115. Kandabashi T, Shimokawa H, Miyata K, et al. Inhibition of myosin phosphatase by upregulated Rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1β. Circulation. 2000;101:1319–1323
  116. Kandabashi T, Shimokawa H, Mukai Y, et al. Involvement of Rho-kinase in agonists-induced contractions of arteriosclerotic human arteries. Arterioscler Thromb Vasc Biol. 2002;22:243–248
  117. Batchelor TJP, Sadaba JR, Ishola A, et al. Rho-kinase inhibitors prevent agonist-induced vasospasm in human internal mammary artery. Br J Pharmacol. 2001;132:302–308

PII: S0021-9150(05)00653-2

doi: 10.1016/j.atherosclerosis.2005.10.005

Atherosclerosis
Volume 185, Issue 2 , Pages 219-226 , April 2006

Article Tools

* Image Usage & Resolution